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Despite multiple approaches to treating metastatic malignant
melanoma, stage IV disease is still associated with a poor prog-
nosis. The most commonly used single agent, dacarbazine (DTIC),
produces a response in the range of 15–20% (Houghton et al,
1992). Combination chemotherapy has yielded higher response
rates but predominantly partial remissions and of short duration
(Legha et al, 1989; McClay et al, 1992). Biological agents such as
interleukin-2 (IL-2) and interferon-alpha (IFN-α ) have been
studied extensively. Response rates have been in the same range as
with DTIC but in contrast to responses achieved with chemo-
therapy, a subset of responses with biological agents is more dura-
ble (Legha, 1997). In recent years several groups have reported
their experiences with combination treatment, biochemotherapy
(Legha, 1997; Khayat et al, 1993; Keilholz et al, 1998; Proebstle
et al, 1998; Richards et al, 1999; Rosenberg et al, 1999).
Unfortunately, many patients do not benefit, whereas others have
responses, some of which are durable and thus very valuable. It
would therefore be of considerable importance if patients with a
high probability of responding could be identified before the start
of treatment using predictive tests. 
As biological agents modulate the activity of various cells in the
immune system, it is reasonable to assume that the therapeutic
effect might depend on the immune status of the patient when
therapy is initiated. Several groups have reported on the impor-
tance of tumour-infiltrating lymphocytes in primary (Clark et al,
1989; Clemente et al, 1996) and metastatic malignant melanoma
(Mihm et al, 1996; Zehntner et al, 1999). Despite some conflicting
results (Balch et al, 1978), lymphocyte infiltration in primary
malignant melanoma seems to be of prognostic significance (Clark
et al, 1989; Clemente et al, 1996; Hansen and McCarten 1974;
Larsen et al, 1978). In regressing melanomas, a predominance of
CD4+ cells has been found (Halliday et al, 1995; Tefany et al,
1991). In metastatic disease, a high CD4/CD8 ratio has indicated a
more favourable prognosis (Hernberg et al, 1997). Our group has
previously shown the importance of CD4+ lymphocytes in mela-
noma metastases for response to IFN-α treatment (Håkansson
et al, 1996). With granulocyte macrophage colony stimulating
factor (GM-CSF) treatment, responding patients showed marked
increases and high absolute numbers of T-cell infiltrates into the
tumour, particularly of the CD4 T-cell subset (Si et al, 1996). This
also concurs well with preliminary data from Zehnenter et al (1999)
suggesting that T-cell infiltration is associated with clinical
response to melanoma immunotherapy. 
Biochemotherapy of metastatic malignant melanoma.
Predictive value of tumour-infiltrating lymphocytes 
A Håkansson1, B Gustafsson2, L Krysander3, B Hjelmqvist4, B Rettrup4 and L Håkansson1
1Department of Oncology; 2Department of Pathology and Cytology; 3Department of Hand and Plastic Surgery, University Hospital, SE-581 85 Linköping;
4Department of Surgery, County Hospital, SE-391 85 Kalmar, Sweden 
Summary The therapeutic efficacy of biochemotherapy in metastatic malignant melanoma still carries a low remission rate, but with some
durable responses. It would therefore be of considerable importance if patients with a high probability of responding could be identified using
predictive tests. The response to interferon-alpha (IFN-α ) correlates with the occurrence of CD4+ lymphocytes identified by fine-needle
aspirates from melanoma metastases (Håkansson et al, 1996). The present investigation studies a possible correlation between tumour-
infiltrating CD4+ lymphocytes in malignant melanoma metastases and the therapeutic effect of biochemotherapy. A total of 25 patients with
systemic and 16 with regional metastatic melanoma were analysed before initiation of biochemotherapy (cis-platinum 30 mg/m2 d.1–3, DTIC
250 mg/m2 d.1–3 i.v. and IFN-α 2b 10 million IU s.c. 3 days a week, q. 28d.). A monoclonal antibody, anti-CD4, was used to identify tumour-
infiltrating lymphocytes in fine-needle aspirates before start of treatment. The presence of these lymphocytes was correlated to response,
time to progression and overall survival. A statistically significant correlation (P = 0.01) was found between the occurrence of CD4+
lymphocytes and tumour regression during biochemotherapy in patients with systemic disease. Out of 14 patients with moderate to high
numbers of infiltrating CD4+ lymphocytes, 12 achieved tumour regression. In contrast, among patients with low numbers of these cells in
metastatic lesions, 8 out of 11 had progressive disease. We also found a significantly longer time to progression (P < 0.003) and overall
survival (P < 0.01) among patients with moderate to high numbers of these cells compared to patients with low numbers of these cells before
initiation of biochemotherapy. Furthermore, in patients with regional disease, we found a significantly longer time to progression (P = 0.01)
and a trend toward a longer overall survival time (P = 0.09). Based on these results and as previously shown with IFN-α therapy alone, there
seems to be a need for CD4+ lymphocytes infiltrating the tumours before the start of biochemotherapy to make the treatment successful.
Determination of these cells in fine-needle aspirates seems to be a method to predict responders to biochemotherapy, thus increasing the
cost–benefit of this treatment strategy considerably, both in terms of patient adverse reactions and health care costs. © 2001 Cancer Research
Campaign http://www.bjcancer.com
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doi: 10.1054/ bjoc.2001.2169, available online at http://www.idealibrary.com on  http://www.bjcancer.comThe aim of the present investigation was therefore to study
whether the presence of tumour-infiltrating CD4+ lymphocytes iden-
tified by fine-needle aspirates of melanoma metastases before treat-
ment is started also correlates with the response to biochemotherapy. 
MATERIALS AND METHODS 
Study population 
This report describes 41 patients with metastatic malignant
melanoma, 26 males and 15 females. The median age was 61 years
(range 36–77) and Karnofsky performance status was 70 or more.
Recurrences were cytologically verified by fine-needle aspirates
before start of treatment. Two groups of patients were studied:
those with regional disease and those with systemic disease. A
total of 16 patients had regional metastases and 25 patients had
systemic disease with the following metastatic sites: 18 lymph
nodes, 8 subcutaneous, 2 cutaneous, 11 lung, 5 liver, 4 spleen, 1
bone, 1 adrenal gland and 2 soft tissue metastases. The number
of metastatic sites in patients with systemic disease was 1 in 9
patients, 2 in 9 patients, 3 in 3 patients and 4 in 4 patients. In the
group with regional metastases in two patients, it was the first
recurrence, in 11 patients, the second recurrence, in 2 patients, the
third and in 1 patient, the fourth regional recurrence. Patients with
symptoms of brain metastases were not included in this study. 
Pre-treatment investigations and treatment schedule 
Pre-treatment investigations included electrocardiogram (ECG),
abdomina computerized tomography (CT), chest X-ray and blood
samples for measurements of creatinine, bilirubin, alkaline phos-
phatase, alanine aminotransferase, lactate dehydrogenase, alpha
amylase, haemoglobin, white blood cells, and thrombocytes. The
treatment schedule was cisplatinum 30 mg/m2 d.1–3 i.v., DTIC 250
mg/m2 d.1–3 i.v. and IFN-α 2b 10 million IU s.c. 3 days a week. The
duration of one cycle was 28 days. One patient also received IL-2
with cycle 1, and two patients were on tamoxifen treatment. 
Fine-needle aspiration of metastases and
immunological staining 
Aspirates were taken from the tumour with a 0.6 mm hypodermic
needle. Only one site and tumour had a fine-needle aspiration in each
patient. The aspirate was smeared on a glass slide and was allowed to
dry in air. At least two smears were then stained for conventional
cytomorphology according to the May–Grunewald–Giemsa method.
In cases without obvious melanin pigment in tumour cells, the diag-
nosis of melanoma was confirmed with immunostaining for vimentin
and protein S-100. Morphological signs of degeneration or necrosis
were registered. 
The slides were air dried and then fixed for 5 min in acetone.
After drying, the slides were washed in phosphate-buffered saline
(PBS), pH 7.6, and incubated with the monoclonal antibody
against CD4 for 30 min (Becton-Dickinson, Stockholm, Sweden).
Mouse IgG (Sigma, Stockholm, Sweden) was used as a negative
control. After washing in PBS, the sections were incubated with
rabbit anti-mouse immunoglobulin (Dakopatts, Z 259) for 30 min,
washed in PBS and incubated with the PAP mouse monoclonal
antibody (Dakopatts, P 850) for 30 min. After washing in PBS, the
slides were incubated in 50 ml PBS containing 40 mg
Diaminobenzidin (DAB, Sigma, Stockholm, Sweden) and 0.6 ml
3% H2O2 for 6 min and washed. The slides were counterstained in
Mayers haematoxylin for 15 min, washed and mounted in
Glycergel (Dakopatts, Sweden). All incubations were performed
in a moist chamber. 
Evaluation of mononuclear cells 
The percentage of CD4+lymphocytes was counted at a magnification
of 400 × using a square inserted into the ocular. In total, 500 cells
were counted in randomly selected areas and the mean of these
counts was used for statistical analysis. When the percentage of
lymphocytes was more than 2%, it was scored as medium/high; a
percentage less than 2% was scored as low. CD4+ cells scored as
lymphocytes had small or medium-sized nuclei and sparse cytoplasm
with distinct cell borders. Macrophages displayed large nuclei and
abundant, generally faintly stained cytoplasm. The proportion of
lymphocytic vs non-lymphocytic CD4+ cells was registered. 
Preparation of tumour biopsies and immunological
staining of tissue sections 
Biopsies from resected tumours were immediately snap-frozen and
stored at –70˚C until further processing. Tissue sections were later
prepared as described previously (Håkansson et al, 1996). The
degree of histopathological tumour regression was evaluated on
negative controls, not incubated with specific primary antibodies. 
Criteria of response in patients with systemic disease
(according to WHO) 
A complete response (CR) was defined as a disappearance of all
known disease. A partial response (PR) was defined as a decrease
by at least 50% in the sum of the products of the largest perpendic-
ular diameters of measurable lesions determined by two observa-
tions not closer than 4 weeks apart. It is not necessary for all
lesions to have regressed for the patient to be classified as having a
partial response, but no lesion should have progressed and no new
lesions should have appeared. Minor regressions did not fulfil the
criteria for partial regression, either because the reduction in the
tumour size was 25–50% or the duration of the response was too
short. A mixed response was defined as a measurable shrinkage of
some lesion and simultaneous progressive disease in some other
metastasis, or the appearance of new lesions. Stable disease (SD)
was defined as a 25% decrease in total tumour size could not be
established nor has a 25% increase in the size of one or more
measurable lesions been demonstrated. In addition, patients with
stable disease will have no appearance of new lesions. Progressive
disease (PD) is defined as a 25% or more increase in the size of at
least one measurable lesion or the appearance of a new lesion. As
the objective of this study was to analyze a correlation between the
occurrence of tumour-infiltrating CD4+ lymphocytes and the anti-
tumour effect of biochemotherapy, significant tumour regression
(more than 25%) in patients with minor regressions and mixed
responses, not fulfilling the formal criteria for partial remission,
were used in the following analysis. 
Evaluation of tumour regression in patients with
regional metastases and criteria of histopathological
tumour regression 
Among patients with regional resectable disease, clinical tumour
response may be difficult to detect based on tumour size only.
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histopathological examination of tumour biopsies. Based on the
description of regressive changes in primary malignant melanoma
in other studies and as previously described by our group
(Håkansson et al, 1996; McGovern, 1975; Kang et al, 1993;
Sondergard and Hou-Jensen, 1985; Ronan et al, 1987) the follow-
ing criteria of tumour regression were used in this study: 
1. Low and variable density of tumour cells, particularly variation
in density within the same tumour nodule 
2. Disorganization of the architecture of the tumour with nests of
remaining tumour cells surrounded by stromal tissue 
3. Fibrosis. 
However, the inflammatory infiltrate was not used as a criterion
of histopathological tumour regression in this study. The signs of
regression vary from no signs to almost complete destruction with
only few tumour cells present. The degree of tumour regression
was considered minor when regressive changes were estimated to
be less than 25% (minor regression) and marked when such
changes were estimated to be more than 25% (marked regression)
of the section area. Tumour regression areas of more than 25% are
generally not found in tumour biopsies from untreated patients
(Håkansson et al, 1998). 
Statistical analyses 
The differences in distribution of inflammatory cells between
patients with tumour response and progressive disease and bet-
ween patients with marked and minor or no histopathological
tumour regression were analyzed using the χ 2 test. 
Survival curves were plotted using the Kaplan–Meier method,
and time to progression and survival comparisons between sub-
groups were performed using the log rank test. 
The study was approved by the ethical committee at the
University Hospital of Linköping, Sweden. 
RESULTS 
Correlation between treatment efficacy and occurrence
of tumour-infiltrating mononuclear cells in patients with
systemic disease 
Reduction in tumour size after biochemotherapy was registered in
15 out of 25 patients with systemic disease. Of these 25, 2 had a
complete remission, 8 had partial remission, 4 had a reduction of
measurable tumours of 25–50%, 1 had a mixed response, 1 had
stable disease and 9 patients had progressive disease. The overall
objective response rate was 40% and 60% of patients achieved at
least a minor or mixed response. The 2 patients who achieved
complete remission later had their treatment changed from
biochemotherapy to IL-2 because of adverse side effects. These
changes in both patients were made after they already had achi-
eved complete remission on the biochemotherapy regimen. One
had progressive disease and died after 3 months, the other is still
disease-free after 42 months. Two patients with partial remission
and 1 patient with a minor response after biochemotherapy achieved
complete remission after surgery; 2 had recurrent disease after 7 and
13 months respectively, and one is still disease-free. 
In order to register any capacity to respond to biochemotherapy,
mixed responses and minor regressions not fulfilling the formal
criteria for partial remission were included in the analysis. The
occurrence of CD4+ lymphocytes in fine-needle aspirates
(Figure 1) in relation to the therapeutic effect of biochemotherapy
Importance of TIL for efficacy of biochemotherapy 1873
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Figure 1 Occurrence of tumour-infiltrating CD4+ lymphocytes in a fine-
needle aspirate from a melanoma metastases before initiation of
biochemotherapy
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Figure 2 Time to progression in patients with systemic disease according
to the number of tumour-infiltrating CD4+ lymphocytes before initiation of
biochemotherapy, P < 0.003
Table 1 Pre-treatment tumour-infiltrating CD4+ lymphocytes in
fine-needle aspirates from patients with systemic disease according to
clinical effect of biochemotherapy
Proportion of No. of patients with tumour-infiltrating CD4+
infiltrating cells lymphocytes according to tumour response
Regression Stable Progressive
disease disease
Low 3 0 8
Moderate/high 12 1 1is shown in Table 1. Obviously there is a close correlation between
the anti-tumour effect and presence of CD4+ lymphocytes. Out of
25 patients, 14 had moderate/high numbers of tumour-infiltrating
CD4+ lymphocytes and 12 out of 14 achieved tumour regression.
In contrast, 8 out of 11 patients with low numbers of these cells
had progressive disease (P = 0.01). 
We also found a significantly longer time to progression 
(P < 0.003) and overall survival (P < 0.01) among patients with
moderate/high numbers of CD4+ lymphocytes compared to
patients with low numbers of these cells before initiation of
biochemotherapy (Figures 2 and 3). 
Correlation between treatment efficacy and occurrence
of tumour-infiltrating mononuclear cells in patients
with regional metastases 
Among patients with regional metastases, it was difficult to ade-
quately determine treatment efficacy based on tumour size only, as
the majority of these patients had their metastases resected after
the first treatment cycle. Therefore, histopathological criteria used
for tumour regression were applied in the evaluation. A total of 10
patients had marked histopathological regression (Figure 4A) of
the resected metastases and 4 patients had only minor or no regres-
sive changes (Figure 4B). After treatment, 2 patients did not
undergo surgery 1 because of extensive progression of the disease
and 1 because of difficulties in performing more extensive surgery
after previous resections. 
Although the number of patients with regional metastases is
small, a similar tendency to that of patients with systemic disease
was found. Of 8 patients with moderate/high numbers of tumour-
infiltrating CD4+ lymphocytes, 7 showed marked histopatholog-
ical regression, in contrast to 3 out of 6 patients with low numbers
of these cells in the metastases. 
Moreover in patients with regional disease, we found a signifi-
cantly longer time to progression (P = 0.01) and a trend toward a
longer overall survival (P = 0.09) among patients with moderate/
high numbers of CD4+ lymphocytes compared with patients with
low numbers of these cells before initiation of biochemotherapy
(Figures 5 and 6). 
DISCUSSION 
In recent years, biochemotherapy has been used by many groups
treating metastatic malignant melanoma (Legha, 1997; Khayat
et al, 1993; Keilholz et al, 1998; Proebstle et al, 1998, Richards
et al, 1999; Rosenberg et al, 1999). A subset of durable, and thus
very valuable, remissions has been shown compared with
chemotherapy alone. As treatment, however, is associated with
significant toxicity and many patients still do not benefit, there is
a great need for predictive tests identifying patients with a high
probability of response. 
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Figure 3 Overall survival in patients with systemic disease according to the
number of tumour-infiltrating CD4+ lymphocytes before initiation of
biochemotherapy, P < 0.01
A B
Figure 4 (A) Marked tumour regression in a tumour biopsy after biochemotherapy. (B) Tumour biopsy without regressive changes after biochemotherapyIn the adjuvant setting also, immunotherapy has shown impor-
tant results on relapse-free (Pehamberger et al, 1998; Grob et al,
1998; Kirkwood et al, 2000) and overall survival (Kirkwood et al,
1996). Today, several different studies are undertaken, where im-
munotherapy is given to high-risk patients. Also in this setting,
however, many patients do not benefit. Because of this, there is a
need for a predictive test that selects patients who are suitable for
this kind of therapy. 
Biological agents modulate various functions in the immune
system. It is thus reasonable to assume that the therapeutic effect
might depend on the presence of certain subsets of mononuclear
cells infiltrating the tumours before treatment is initiated. There-
fore the present study analysed the presence of tumour-infiltrating
lymphocytes in melanoma metastases before the start of bio-
chemotherapy. 
As has previously been shown with IFN-α therapy (Håkansson
et al, 1996), the present study demonstrated a close correlation
between the occurrence of CD4+ lymphocytes and the therapeutic
benefit of biochemotherapy with IFN-α , DTIC and cisplatinum. In
patients with systemic disease, 12 out of 14 of those with moderate/
high infiltration of CD4+ lymphocytes in the tumours achieved
tumour regression. In contrast, among patients with low infiltration
of these cells, 8 out of 11 had progressive disease. The presence of
a moderate/high infiltration of CD4+ lymphocytes in the metastases
was also found to correlate with a significantly longer time to
progression and a significantly longer overall survival compared to
patients with a low infiltration. These results are of great impor-
tance as many responses in melanoma treatment are, unfortunately,
of short duration and do not show any impact on survival. Thus, the
present method not only predicts responders but also identifies
patients with a high probability of durable remission. 
In order to evaluate properly a possible correlation between
response to treatment and a parameter of potential predictive
value, it is necessary to include all patients with measurable tum-
our regression in the analysis, i.e. at least those with minor regres-
sion and mixed responses. The reason why short-lived, minor
regressions do not continue and develop into partial or complete
remissions is not clear, but it is reasonable that the outcome of
several months of immunotherapy is the end result of a multi-step
process, e.g. initial immune-mediated lysis of tumour cells, selec-
tion of non-immunogenic tumour cell clones, and down-regulation
of the immune response to the tumour (Håkansson et al, 1999).
Thus, in order not to misjudge the possibility of the immune
system of these patients responding to immunotherapy, significant
minor and mixed responses have to be included in the analyses. If
only patients with partial or complete remissions are regarded as
responders, other patients with measurable regression will erro-
neously be allocated to the group of non-responders, which will
obscure the results. This misinterpretation of data may be one
reason why tests of predictive value for response to immuno-
therapy have been difficult to find. 
Finding immunological tests of predictive value for biochemo-
therapy might, of course, be even more difficult as some responses
seen with combination treatment might depend on the effect of the
cytotoxic drugs only. However, a predictive value of the presence
of CD4+ tumour-infiltrating lymphocytes was actually found in the
present study. The reason for this can be either that patients with an
immune status allowing CD4+ lymphocytes to infiltrate into the
tumours respond to the type of chemotherapy used in the present
study or that there is a synergistic effect between IFN-α and these
cytotoxic drugs. It has been demonstrated that cisplatinum can
enhance the immune reactivity to the tumour by increasing the
expression of Fas (Mizutani et al, 1998) on tumour cells and also
inhibiting the production of the IL-1 receptor antagonist (Arenberg
et al, 1995). 
The need for CD4+ lymphocytes to infiltrate the tumours in
order to make the treatment successful agrees well with reports
from other groups on the importance of tumour-infiltrating
lymphocytes in primary and metastatic melanoma (Clark et al,
Importance of TIL for efficacy of biochemotherapy 1875
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Figure 5 Time to progression in patients with regional disease according to
the number of tumour-infiltrating CD4+ lymphocytes before initiation of
biochemotherapy, P = 0.01
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Figure 6 Overall survival in patients with regional disease according to the
number of tumour-infiltrating CD4+ lymphocytes before initiation of
biochemotherapy, P = 0.091989; Clemente et al, 1996; Mihm et al, 1996; Zehntner et al,
1999; Hernberg et al, 1997; Si et al, 1996). 
CD4+ lymphocytes generally have been considered to be im-
munoregulatory but have, in recent years, also been found to have
a direct cytotoxic activity (Thomas and Hersey, 1998). The exact
mechanism, however, still remains uncertain. Our group has previ-
ously shown that IFN-α treatment facilitates the migration of
CD4+ cells from the stroma close to tumour cells and that the
extent of the tumour areas with regressive changes was signifi-
cantly enhanced after IFN-α treatment (Håkansson et al, 1998).
These results also support the view that the CD4+ cells interact
directly with the tumour cells. 
Based on the results with biochemotherapy shown in this study,
and as previously shown with IFN-α therapy alone, there is a need
for CD4+ lymphocytes to infiltrate the tumours in order to make
the treatment successful. Thus, determining tumour-infiltrating
CD4+ lymphocytes obtained by fine-needle aspiration seems to 
be a method of predicting responders. This will increase the
cost–benefit of this treatment strategy considerably, both in terms
of patient adverse reactions and health care costs. 
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